Merck & Co., Inc. vs Health Care Select Sector SPDR Fund — how do they compare? Merck & Co., Inc. trades at $148 (market cap $366.28B), while Health Care Select Sector SPDR Fund trades at $167.05. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Health Care Select Sector SPDR Fund pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Health Care Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| MRK | XLV | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | — |
52-Week High | $156.43 | $175.68 |
52-Week Low | $77.60 | $134.13 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
XLV trades at $167.16, down 2.5% amid testing key support levels, with technical indicators showing mixed signals between bullish moving averages and bearish oscillators. The healthcare ETF maintains defensive appeal with upcoming dividend payments and steady institutional interest, though recent options activity shows increased put volume. Healthcare sector momentum remains supported by strong earnings and defensive positioning in volatile markets.
Outlook remains cautiously optimistic given healthcare's defensive characteristics and potential Fed rate hike benefits, though near-term technical weakness and sector-specific headwinds like drug trial failures present risks. The ETF's low expense ratio and diversification across 60 healthcare stocks provide stability for long-term investors seeking sector exposure.
Trailing returns across standard periods
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →